TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward
Gudaitis, President and Chief Executive Officer of Acerus, is scheduled
to present an overview of the company at the Bloom Burton &
Co. Healthcare Investor Conference. Mr. Gudaitis’ address will take
place at the Metro Toronto Convention Centre, 255 Front Street W,
Toronto, Ontario on May 1, 2019 at 10:00 a.m. Eastern Time.
The presentation will be webcast live. To access the webcast, please
visit http://wsw.com/webcast/bloomburton4/asp.to/.
The webcast replay will remain available on the company’s website, www.aceruspharma.com
for 90 days following the live presentation.
About the conference
The Bloom Burton & Co. Healthcare Investor Conference brings together
U.S., Canadian and International investors who are interested in the
latest developments in the Canadian healthcare sector. Attendees will
have an opportunity to obtain corporate updates from the premier
Canadian publicly traded and private companies through presentations and
private meetings.
About Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation is a Canadian-based specialty
pharmaceutical company focused on the development, manufacture,
marketing and distribution of innovative, branded products that improve
patient experience, with a primary focus in the field of men’s and
women’s health. The Company commercializes its products via its own
salesforce in Canada, and through a global network of licensed
distributors in the U.S. and other territories.
Acerus’ shares trade on TSX under the symbol ASP. For more information,
visit www.aceruspharma.com
and follow us on Twitter
and LinkedIn.
Forward-Looking Information
Information in this press release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information are
assumptions regarding our future operational results. These assumptions,
although considered reasonable by the company at the time of
preparation, may prove to be incorrect. Readers are cautioned that
actual performance of the company is subject to a number of risks and
uncertainties, and could differ materially from what is currently
expected as set out above. For more exhaustive information on these
risks and uncertainties you should refer to our annual information form
dated March 4, 2019 that is available at www.sedar.com.
Forward-looking information contained in this press release is based on
our current estimates, expectations and projections, which we believe
are reasonable as of the current date. You should not place undue
importance on forward-looking information and should not rely upon this
information as of any other date. While we may elect to, we are under no
obligation and do not undertake to update this information at any
particular time, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws.
Contacts
Robert Motz
Chief Financial Officer
Acerus Pharmaceuticals
Corporation
rmotz@aceruspharma.com
(905)
817-8288